Bio-Rad Laboratories, Inc. Class A Common Stock vs LyondellBasell Industries NV — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $357.58 (market cap $9.43B), while LyondellBasell Industries NV trades at $62.89 (market cap $20.67B). The key difference: LyondellBasell Industries NV is far larger — about 2.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and LyondellBasell Industries NV pays a 6.44% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | LYB | |
|---|---|---|
Market Cap | $9.43B | $20.67B |
Sector | Health | Basic Materials |
52-Week High | $356.25 | $82.38 |
52-Week Low | $241.71 | $42.28 |
Enterprise Value | $9.18B | $32.26B |
Dividend Yield | — | 6.44% |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
LYB trades at $62.97, up 0.51% today, with a bullish technical signal from moving averages and a consensus analyst price target of $70.56. Recent Q2 2026 earnings of $4.30 per share beat estimates, driven by improved margins from supply disruptions and cost cuts. However, 2025 fundamentals show declining revenue to $30.15B and a net loss of $745M, though cash flow remains positive. The stock is near its 52-week high of $83.94, reflecting optimism around operational improvements.
Outlook: Near-term upside exists from earnings momentum and favorable supply dynamics, but risks include volatile chemical margins and high debt. Analyst sentiment is mixed with 46% buy ratings, suggesting cautious optimism amid cyclical challenges.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →